In a recent article titled “ Big Pharma says ‘Thanks, but No Thanks’ to their own HEOR groups, ” Professor Scott Ramsey from ...

In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI ponders the next big developments and breakthroughs he expects to see in the ...

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...

Statistically significant means there is a very high likelihood the drug impacted its target. But if data are not clinically ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

Monica Martin de Bustamante, senior partner and head of advisory at Trinity Life Sciences, spoke with Pharmaceutical ...

In this Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, speaks about how distrust and uncertainty ...

New cases are still being recorded, and the impact of long COVID has yet to be fully determined. Invivyd announced a ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...